Summit supports its drug discovery programmes with two world-leading technology platforms in zebrafish chemical genomics and carbohydrate chemistry, and generates increasing revenues by offering these platforms to the wider pharmaceutical and biotechnology industry. Summit has a broad and diverse pipeline of clinical, pre-clinical and discovery stage programmes targeting serious diseases indications, including neurological-disorders (neurodegenerative and neuromuscular disorders), infectious diseases, cancer, ophthalmic diseases and regenerative medicine. The Company's pipeline has been built through a combination of focused acquisitions and in-house development of promising research programmes.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.